Monopar Therapeutics (MNPR) Current Assets: 2016-2020
Historic Current Assets for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $18.1 million.
- Monopar Therapeutics' Current Assets rose 254.05% to $18.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.1 million, marking a year-over-year increase of 254.05%. This contributed to the annual value of $13.2 million for FY2019, which is 82.42% up from last year.
- According to the latest figures from Q3 2020, Monopar Therapeutics' Current Assets is $18.1 million, which was up 42.09% from $12.7 million recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Current Assets peaked at $18.1 million during Q3 2020, and registered a low of $2.1 million during Q4 2016.
- For the 3-year period, Monopar Therapeutics' Current Assets averaged around $9.5 million, with its median value being $7.9 million (2018).
- In the last 5 years, Monopar Therapeutics' Current Assets surged by 335.82% in 2017 and then slumped by 35.23% in 2019.
- Quarterly analysis of 5 years shows Monopar Therapeutics' Current Assets stood at $2.1 million in 2016, then surged by 335.82% to $9.1 million in 2017, then fell by 20.58% to $7.3 million in 2018, then skyrocketed by 82.42% to $13.2 million in 2019, then skyrocketed by 254.05% to $18.1 million in 2020.
- Its Current Assets stands at $18.1 million for Q3 2020, versus $12.7 million for Q2 2020 and $12.7 million for Q1 2020.